52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

Study Summary

This is a 52-week open label single arm study + 24-Month long-term safety extension to investigate the effects of XYOSTED, as testosterone replacement therapy, on adolescent males with either primary or secondary hypogonadism. The study aims to determine the effectiveness of XYOSTED measured by continuation or induction of puberty in addition to XYOSTED dosage, safety and testosterone levels.

Conditions

Hypogonadism, Male

Interventions / Drugs

Testosterone enanthate

View on ClinicalTrials.gov ↗

Sponsor

HALO

Halozyme Therapeutics

Drug Delivery

D43/100

Study Details

Enrollment100 participants

Primary Completion—

Lead SponsorHalozyme Therapeutics

Data Retrieved2026-04-11 04:15:08.366888+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.